Cyto

toxic Payload Discovery

AD

C Linker Design

ADC

Des

ign

and Development

Analytics

Bioassays

ADC Matrix Assessment

Cytotoxicity Assays

Paylo

ad-Linker Manufacture

Cell Line Development

A�nity Maturation

GMP ADC Manufacture

Developability Assessment

Man

ag

ed In Vivo Studies

Target Identi�cation

Autom

ated

Antib

ody Discovery

Antibody Humanisation

Imm

unogenicity Assessm

ent

Analytics Bioassays

Ig Class & Isotype Switching

Cell S

ignalling Analysis

PE

Gylation

Bi

nding & Competition Assays

Cell V

iability Assays

Fc B

indi

ng

and Functional Assays

Cell Banking

Cell L

ine Stability Studies

200

L no

n-GMP Toxicology Batch

500

L n

on-GMP Engineering Run

Upstream Process Developm

ent

Downstream Process Development

50

0 L GMP Batch

Antib

ody D

rug Substance

AD

C Drug Substance

Form

ulation Development

50 L

Con�rmation Run

Hyb

ridom

a Sequencing

Tran

sient Expression

Phas

e I &

Phase II Clinical Trial Supply

Fill Finish

Cytok

ine

Relea

se Assays

Integrated Discovery to Manufacturing

for Biologics and ADCs

Route Design & Scale Up

Form

ulation Development

Drug Resistance Assays

Man

aged In Vivo Studies

Stability Assessment

Cyto

toxic Payload Discovery

AD

C Linker Design

ADC

Des

ign

and Development

Analytics

Bioassays

ADC Matrix Assessment

Cytotoxicity Assays

Paylo

ad-Linker Manufacture

Cell Line Development

A�nity Maturation

GMP ADC Manufacture

Developability Assessment

Man

ag

ed In Vivo Studies

Target Identi�cation

Autom

ated

Antib

ody Discovery

Antibody Humanisation

Imm

unogenicity Assessm

ent

Analytics Bioassays

Ig Class & Isotype Switching

Cell S

ignalling Analysis

PE

Gylation

Bi

nding & Competition Assays

Cell V

iability Assays

Fc B

indi

ng

and Functional Assays

Cell Banking

Cell L

ine Stability Studies

200

L no

n-GMP Toxicology Batch

500

L n

on-GMP Engineering Run

Upstream Process Developm

ent

Downstream Process Development

50

0 L GMP Batch

Antib

ody D

rug Substance

AD

C Drug Substance

Form

ulation Development

50 L

Con�rmation Run

Hyb

ridom

a Sequencing

Tran

sient Expression

Phas

e I &

Phase II Clinical Trial Supply

Fill Finish

Cytok

ine

Relea

se Assays

Integrated Discovery to Manufacturing

for Biologics and ADCs

Route Design & Scale Up

Form

ulation Development

Drug Resistance Assays

Man

aged In Vivo Studies

Stability Assessment

Abzena’s Second Biopharmaceutical Discovery & Development Symposium

19th February 2020Babraham Research CampusCambridge

Cytotoxic Payload Discovery

ADC Linker Design

ADC Design and Development

Analytics

Bioassays

ADC Matrix Assessment Cytotoxicity Assays

Payload-Linker Manufacture

Cell Line Developm

ent

A�nity Maturation

GMP ADC Manufacture

Developability Assessment

Managed In Vivo Studies

Target Identi�cation

Auto

mated Antibody Discovery

Antibody Humanisation

Immunogenicity Assessment

Analytics

Bioassays

Ig Class & Isotype Switching

Cell Signalling Analysis

PEGylation

Binding & Competition Assays

Cell Viability Assays

Fc Binding and Functional Assays

Cell Banking

Cell Line Stability Studies

200 L non-GMP Toxicology Batch

500 L non-GMP Engineering Run

Upstream Process Development

Downstream Process Development

500 L GMP Batch

Antibody Drug Substance

ADC Drug Substance

Formulation Development 50 L Con�rm

ation Run

Hybridoma Sequencing

Transient Expression

Phase I & Phase II Clinical Trial Supply

Fill Finish

Cyto

kine Release Assays

Integrated Discovery to Manufacturing

for Biologics and ADCs

Route Design & Scale Up Formulation D

evelopment

Drug Resistance Assays

Managed In Vivo Studies

Stability Assessment

Abzena’s Second Biopharmaceutical Discovery & Development Symposium19th February, Babraham Research Campus CambridgeBringing you the latest innovations in the development of biologics and bioconjugatesAbzena are hosting the second Biopharmaceutical Discovery & Development Symposium to showcase the latest technologies and advancements in the biologics field. This will include case studies on how these have been successfully used by developers to efficiently and effectively create biopharmaceuticals to address significant unmet medical needs.

Tours of state-of-the-art laboratoriesThere will also be tours of state-of-the-art laboratories used in Discovery, Immunology, Bioassays, Protein Engineering, Bioconjugation, Bioanalytics and Cell Line Development with demonstrations of how these are used in the drug development process.

The symposium will cover the latest developments in: - Antibody Discovery & Design - Working with novel formats in antibody development - Assessing developability and reducing the risk on route to IND - Cell Line Development and improving titre with reduced timelines - Antibody Drug Conjugates, evaluating linker-payload options effectively - Developing integrated programs and accelerating timelines

LocationCambridge BuildingBabraham Research CampusBabraham, CambridgeCB22 3AT, UK

TransportationComplimentary transportation is provided between Cambridge Train Station and the venue. Cambridge is easily accessible from Stansted airport which connects to most European airports. Registration

Registration is free and open to all. Please fill out the registration form at:

www.abzena.com/symposium

Date and time19th February 20209:00am - 6:00pm 9am Registration & Coffee(5pm Drinks Reception)

Cytotoxic Payload Discovery

ADC Linker Design

ADC Design and Development

Analytics

Bioassays

ADC Matrix Assessment Cytotoxicity Assays

Payload-Linker Manufacture

Cell Line Developm

ent

A�nity Maturation

GMP ADC Manufacture

Developability Assessment

Managed In Vivo Studies

Target Identi�cation

Auto

mated Antibody Discovery

Antibody Humanisation

Immunogenicity Assessment

Analytics

Bioassays

Ig Class & Isotype Switching

Cell Signalling Analysis

PEGylation

Binding & Competition Assays

Cell Viability Assays

Fc Binding and Functional Assays

Cell Banking

Cell Line Stability Studies

200 L non-GMP Toxicology Batch

500 L non-GMP Engineering Run

Upstream Process Development

Downstream Process Development

500 L GMP Batch

Antibody Drug Substance

ADC Drug Substance

Formulation Development 50 L Con�rm

ation Run

Hybridoma Sequencing

Transient Expression

Phase I & Phase II Clinical Trial Supply

Fill Finish

Cyto

kine Release Assays

Integrated Discovery to Manufacturing

for Biologics and ADCs

Route Design & Scale Up Formulation D

evelopment

Drug Resistance Assays

Managed In Vivo Studies

Stability Assessment

Agenda9am Registration & Coffee

9.30am Chairperson’s Opening RemarksDr Campbell Bunce - CSO, Abzena

9.45am Antibody Discovery, Affinity Maturation and Developability Screening from Large Mammalian Display LibrariesDr John McCafferty - CEO & Founder, IONTAS

10:30am Immunomodulation in Cancer Beyond PD-1 and PD-L1Dr Matthew McCourt - SVP Research Immunology, Kymab

11:15am Coffee, Networking and Poster Viewing

11:35am De-Risking ADC Development Through Design and Developability AssessmentDr Mark Frigerio - VP Design and Development, Abzena

12:05pm MultiLink and its Benefits for ADC DevelopmentNathalie Bellocq - Project Manager, Debiopharm

12:35pm Lunch, Networking and Poster Viewing

1:20pm The Design and Delivery of Integrated Drug Discovery ProgramsDr Simon Thompson - Executive Vice President, Rx&D RxCelerate Limited

2:05pm Lab Tours & Coffee Break

3:30pm Monoclonal Antibody Generation Against Native Membrane Proteins with Nano-membrane TechnologyDr Maria L. Knudsen - Salipro Biotech

4:00pm The Progression of Magacizumab, a Humanised Monoclonal Antibody for the Treatment of Neovascular Ocular Disease and CancerDr John Greenwood - Hugh Davson Professor of Biomedical ResearchUniversity College London

4:45pm Chairperson’s Closing Remarks

5:00pm Drinks Reception

Cyto

toxic Payload Discovery

AD

C Linker Design

ADC

Des

ign

and Development

Analytics

Bioassays

ADC Matrix Assessment

Cytotoxicity Assays

Paylo

ad-Linker Manufacture

Cell Line Development

A�nity Maturation

GMP ADC Manufacture

Developability Assessment

Man

ag

ed In Vivo Studies

Target Identi�cation

Autom

ated

Antib

ody Discovery

Antibody Humanisation

Imm

unogenicity Assessm

ent

Analytics Bioassays

Ig Class & Isotype Switching

Cell S

ignalling Analysis

PE

Gylation

Bi

nding & Competition Assays

Cell V

iability Assays

Fc B

indi

ng

and Functional Assays

Cell Banking

Cell L

ine Stability Studies

200

L no

n-GMP Toxicology Batch

500

L n

on-GMP Engineering Run

Upstream Process Developm

ent

Downstream Process Development

50

0 L GMP Batch

Antib

ody D

rug Substance

AD

C Drug Substance

Form

ulation Development

50 L

Con�rmation Run

Hyb

ridom

a Sequencing

Tran

sient Expression

Phas

e I &

Phase II Clinical Trial Supply

Fill Finish

Cytok

ine

Relea

se Assays

Integrated Discovery to Manufacturing

for Biologics and ADCs

Route Design & Scale Up

Form

ulation Development

Drug Resistance Assays

Man

aged In Vivo Studies

Stability Assessment

About AbzenaAbzena is a life sciences group with its headquarters in the UK and two sites in the US. Abzena provides the most complete set of solutions in integrated early discovery to mid-phase biotherapeutic and ADC drug development services in the pharmaceutical industry.

Working with companies and academic groups all over the world, including most of the top 20 biopharmaceutical companies, Abzena supports the development and manufacture of better treatments for patients. Multiple biologics which have been created using Abzena’s technologies are currently being progressed through clinical development.

www.abzena.com

Cambridge, UK: +44 1223 903498 Bristol, PA, USA: +1 215-788-3603 San Diego, CA, USA: +1 858-550-4094